Lin Bioscience Inc (6696)

Currency in TWD
569.00
+86.50(+17.93%)
Closed·
Advertisement
Unusual trading volume
Trading near 52-week High
6696 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
486.50569.00
52 wk Range
136.00569.00
Key Statistics
Bid/Ask
222.00 / 223.50
Prev. Close
143.5
Open
490
Day's Range
486.5-569
52 wk Range
136-569
Volume
2.69M
Average Volume (3m)
620.72K
1-Year Change
318.3824%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6696 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
28/04/2026
EPS / Forecast
-8.90 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare 6696 to Peers and Sector

Metrics to compare
6696
Peers
Sector
Relationship
P/E Ratio
−34.6x−4.8x−0.4x
PEG Ratio
0.39−0.130.00
Price/Book
4.4x2.6x2.6x
Price / LTM Sales
-26.1x3.0x
Upside (Analyst Target)
-118.4%49.7%
Fair Value Upside
Unlock−12.9%7.3%Unlock

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
153.92K0.19%74.27M
Other Institutional Investors
8.16M9.85%3.94B
Public Companies & Retail Investors
74.51M89.96%35.95B
Total
82.83M100.00%39.96B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Goldman Sachs Group, Inc.2.98%2,469,0001,191,293
Beiley Biofund Inc.1.87%1,552,657749,157

FAQ

What Is the Lin Bio (TPEX: 6696) Share Price Today?

The Lin Bio stock price today is 569.00 TWD.

What Stock Exchange Does Lin Bio (6696) Trade On?

Lin Bio is listed and trades on the Taipei Exchange.

What Is the Ticker (Stock Symbol) for Lin Bio?

The stock symbol (also called a 'ticker') for Lin Bio is "6696."

What Is the Current Lin Bio Market Capitalisation?

As of today, Lin Bio (TPEX: 6696) market cap is 53.67B TWD.

What Is Lin Bio's (6696) Earnings Per Share (TTM)?

The Lin Bio EPS is currently -16.60 (Trailing Twelve Months).

Is 6696 a Buy or Sell From a Technical Analyst Perspective?

Based on today's Lin Bio moving averages and other technical indicators, the daily buy/sell signal for 6696 stock is Strong Buy.

How Many Times Has Lin Bio Stock Split?

Lin Bio has split 1 times. (See the 6696 stock split history page for full effective split date and price information.)

What is the current trading status of Lin Bio (TPEX: 6696)?

As of 08/07/2026, Lin Bio (6696) is trading at a share price of 569.00 TWD, with a previous close of 143.50 TWD. The stock has fluctuated within a day range of 486.50 TWD to 569.00 TWD, while its 52-week range spans from 136.00 TWD to 569.00 TWD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.